A multidisciplinary approach is most effective for treating difficult-to-control AD in children and adolescents.

Guselkumab has shown improvements in skin clearance, scalp itch, and patient-report health-related QoL in skin of colour patients.

Multilevel changes may be needed to reduce the impact of acne-related stigma and barriers to acne treatment in trans patients.

According to a recent study, there is a high prevalence of HS in Finland among patients in their 30s.

A recent medical student-led initiative has shown that early acne education can help improve health literacy and treatment compliance.

Dermatologists are more likely than other physicians to prescribe standard of care therapies to pediatric HS patients.

IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical AD compared to other biologics.

The AAAAI/ACAAI JTF has published updated AD guidelines based on new available treatments and evidence-based recommendations.